Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL versus SOLOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL versus SOLOSEC.
FLAGYL vs SOLOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
Secnidazole is a nitroimidazole antibiotic that exerts its bactericidal activity by entering the bacterial cell and inhibiting DNA synthesis. The nitro group of secnidazole is reduced intracellularly to form free radicals and other reactive intermediates that damage bacterial DNA.
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
2 g orally as a single dose for trichomoniasis.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
Terminal elimination half-life approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
Renal: approximately 75% as unchanged drug; fecal/biliary: minor (estimated <10%)
Category C
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic